{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-056122","form_type":"8-K","ticker":"DYN","cik":"0001818794","company_name":"Dyne Therapeutics, Inc.","filed_at":"2023-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.654302+00:00","generated_at":"2026-06-09T06:11:00.886542+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Dyne reports Q3 net loss $60.2M, cash $157.8M; clinical data due Jan 2024","bullets":["Cash, cash equivalents and marketable securities of $157.8M; funding expected through 2024.","Net loss of $60.2M ($0.99 per share) vs. $41.4M ($0.80) in Q3 2022; R&D expenses rose to $55.3M from $34.7M.","ACHIEVE trial (DYNE-101 in DM1) fully enrolled through 3.4 mg/kg; dose escalation to 6.8 mg/kg enrolling; over 150 doses, no anemia or discontinuations.","DELIVER trial (DYNE-251 in DMD) fully enrolled through 10 mg/kg; dose escalation to 20 mg/kg enrolling; over 175 doses, no anemia or discontinuations.","Initial safety, splicing, dystrophin and functional data from both trials expected around J.P. Morgan Healthcare Conference in early January 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-056122","json":"https://secwatch.observer/filing/0000950170-23-056122.json","markdown":"https://secwatch.observer/filing/0000950170-23-056122.md","text":"https://secwatch.observer/filing/0000950170-23-056122.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818794/000095017023056122/0000950170-23-056122-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818794/000095017023056122/dyn-20231030.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T06:11:00.886542+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8432e40366bc61a3d88e97352dd03d61fda3d4bd","claim":"Dyne Therapeutics, Inc. reported September 30, 2023 results: net income Net loss for the quarter ended September 30, 2023 was $60.2 million, or $0.99 per basic and diluted share., EPS $0.99.","evidence_excerpt":"Net loss for the quarter ended September 30, 2023 was $60.2 million, or $0.99 per basic and diluted share.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017023056122/0000950170-23-056122-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"September 30, 2023"},{"label":"Net income","value":"Net loss for the quarter ended September 30, 2023 was $60.2 million, or $0.99 per basic and diluted share."},{"label":"EPS","value":"$0.99"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}